Skip to main content

Table 3 Specific characteristics of the 98 HIV-infected patients

From: Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological status

Variables (%)

Total

Survived the ICU

Died in the ICU

p value

 

(n = 98)

(n =62)

(n =36)

 

HAART

    

No past history of HAART

24 (24.5)

16 (25.8)

8 (22.2)

0.669

No HAART at the admission + no introduction in ICU

45 (45.9)

28 (45.2)

17 (47.2)

 

No HAART at the admission + introduction in ICU

9 (9.2)

7 (11.3)

2 (5.6)

0.106

HAART active at the admission and pursued

20 (20.4)

16 (25.8)

4 (11.1)

 

HAART active at the admission and stopped

24 (24.5)

11 (17.7)

13 (36.1)

 

Introducing or pursuing HAART in ICU

29 (29.6)

23 (37.1)

6 (16.7)

0.032

Immunovirological data

    

Mean ± SD CD4 (/mm3) §

173.5 ± 192

176.3 ± 197.1

168.7 ± 185.8

0.701

Mean ± SD HIV RNA VL (103 copies/ml)¶

274. 8 ± 664.9

282.6 ± 709.5

261.1 ± 591

0.975

CD4high (≥200/mm3)

30 (32.3)

20 (33.9)

10 (29.4)

0.656

CD4low (<200/mm3)

63 (67.7)

39 (66.1)

24 (70.6)

 

Combined

CD4high + VLhigh

14 (18.4)

9 (18.4)

5 (18.5)

 

subgroups

CD4high + VL low

12 (15.8)

10 (20.4)

2 (7.4)

0.429

 

CD4low + VLhigh

40 (52.6)

25 (51)

15 (55.6)

 
 

CD4low + VLlow

10 (13.2)

5 (10.2)

5 (18.6)

 
  1. §93 patients; 77 patients.
  2. ICU, intensive care unit; CD4, lymphocyte T CD4(+); CD4high, ≥200 cell/mm3; CD4low, <200 cell/mm3; VL, viral load; VLhigh, ≥1,000 copy/ml; VLlow, <1,000 copy/ml; HAART, highly active antiretroviral therapy.
  3. *p is significant.